טוען...
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure
Despite the consensus around the clinical potential of the α-emitting radionuclide astatine-211 ((211)At), there are only a limited number of research facilities that work with this nuclide. There are three main reasons for this: (1) Scarce availability of the nuclide. Despite a relatively large num...
שמור ב:
| הוצא לאור ב: | Cancer Biother Radiopharm |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Mary Ann Liebert, Inc., publishers
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7465635/ https://ncbi.nlm.nih.gov/pubmed/32077749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cbr.2019.3055 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|